ClinicalTrials.gg
Not yet recruitingNCT07941986Updated Nov 17, 2026

Association Between Maternal Intrapartum Pethidine Exposure and Respiratory Depression in Late-Preterm Newborns

An observational study in Neonatal Respiratory Depression, Late Preterm Infant and Meperidine, sponsored by Egyptian Chinese University. Not yet recruiting. Open to participants aged 1 Minute to 24 Hours, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-17.

Sponsored by Egyptian Chinese University · Observational

Updated Nov 17, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
320
Ages
1 Minute to 24 Hours
Sex
All
01

Study summary

This study aims to investigate whether exposure to pethidine during labor is associated with breathing difficulties in late-preterm newborns. Late-preterm babies are those born between 34 weeks and 36 weeks plus 6 days of pregnancy. Although they are close to full term, they may still have an increased risk of breathing problems after birth.

The study will be conducted at two hospitals: Zagazig University Hospitals in Egypt and Royale Hayat Hospital in Kuwait. It will include approximately 320 mothers and their newborn babies.

The researchers will prospectively observe two groups of mothers receiving combined spinal-epidural (CSE) analgesia during labor. The first group will include mothers who receive pethidine in addition to CSE analgesia as part of their clinical care. The second group will include mothers who receive CSE analgesia without pethidine. The decision to administer pethidine will remain entirely with the treating medical team and will not be determined by the research study.

The main purpose is to compare the occurrence of clinically significant breathing difficulties in newborns during the first 24 hours after birth. The study will also assess the need for newborn resuscitation, oxygen therapy, respiratory support, admission to the neonatal intensive care unit, feeding difficulties, and other neonatal outcomes. Maternal outcomes will also be evaluated.

The findings may improve understanding of the association between maternal intrapartum pethidine exposure and neonatal health, particularly when pethidine is used as an adjunct during labor to facilitate cervical effacement, ripening, and dilatation alongside combined spinal-epidural analgesia. The results may help clarify the potential neonatal respiratory risks associated with this practice, support evidence-based decisions regarding intrapartum pain management and cervical preparation, and contribute to improving maternal and neonatal safety.

Read the detailed description

Late-preterm infants, defined as newborns delivered between 34+0 and 36+6 weeks of gestation, have a higher risk of neonatal complications than term infants because of their relative physiological immaturity. Respiratory morbidity is particularly important in this population, as these newborns may experience respiratory difficulties requiring additional assessment, monitoring, or respiratory support after birth.

Pethidine (meperidine) is an opioid medication used in obstetric practice during labor. In addition to its analgesic properties, it may be administered as an adjunct during labor in certain clinical settings to facilitate cervical effacement and dilatation. Maternal intrapartum administration of pethidine results in placental transfer and fetal exposure. Because opioids can depress the central nervous system and respiratory drive, exposure close to delivery may potentially affect neonatal respiratory adaptation after birth.

The potential effects of maternal pethidine exposure are particularly relevant in late-preterm newborns, whose respiratory and neurological systems are not yet fully mature. However, the relationship between intrapartum pethidine exposure and clinically significant neonatal respiratory depression in this population requires further investigation, particularly in the context of contemporary obstetric analgesia practices.

This study will investigate the association between maternal intrapartum pethidine exposure and neonatal respiratory outcomes among late-preterm newborns delivered in two different clinical settings. The study will focus on mothers receiving combined epidural analgesia, comparing those who also receive pethidine as part of their routine clinical care with those who receive combined epidural analgesia without pethidine.

The research will follow a prospective observational cohort design. Maternal medication exposure and relevant obstetric characteristics will be documented, together with neonatal clinical assessments and outcomes. The administration of pethidine and the selection of analgesic techniques will remain entirely at the discretion of the treating obstetric and anesthetic teams. The research will not introduce, assign, or modify any medication or clinical intervention.

By examining the association between maternal pethidine exposure, obstetric characteristics, and neonatal outcomes, this study aims to provide clinically relevant evidence regarding the potential respiratory effects of intrapartum opioid exposure in late-preterm newborns. The findings may help inform evidence-based obstetric practices concerning the adjunctive use of pethidine during cervical effacement and dilatation, alongside maternal analgesia, while supporting appropriate neonatal monitoring and early recognition of respiratory complications.

02

Conditions studied

  • Neonatal Respiratory Depression
  • Late Preterm Infant
  • Meperidine
  • Cervical Ripening
  • Cervical Dilatation
  • Pregnant Women
  • Premature Birth

Browse trials for

Keywords

  • Pethidine
  • Meperidine
  • Maternal Pethidine Exposure
  • Intrapartum Opioid Exposure
  • Neonatal Respiratory Depression
  • Neonatal Respiratory Morbidity
  • Late-Preterm Infants
  • Late-Preterm Birth
  • Combined Spinal-Epidural Analgesia
  • Epidural Analgesia
  • Cervical Effacement
  • Cervical Dilatation
  • Cervical Ripening
  • Cervical Maturation
  • Labor Progression
  • Neonatal Outcomes
  • Maternal Analgesia
  • Prospective Observational Cohort Study
  • Neonatal Respiratory Outcomes
  • Pethidine Exposure Before Delivery
03

In context

Premature Birth

2,556 studies on the registry are indexed under Premature Birth; 504 are open to participants now.

This study's planned enrollment of 320 is above the median of 120 across 808 observational studies indexed under Premature Birth.

Browse Premature Birth studies →

Lead sponsor

Egyptian Chinese University is the lead sponsor of 12 studies on the registry; 5 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
1 Minute to 24 Hours
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

late-preterm newborns delivered between 34+0 and 36+6 weeks of gestation. The study will include 320 newborns divided into two cohorts: 160 newborns exposed to maternal intrapartum pethidine alongside combined spinal-epidural analgesia and 160 newborns whose mothers received combined spinal-epidural analgesia without pethidine. Maternal clinical characteristics and intrapartum analgesic exposure will also be documented to assess their association with neonatal respiratory outcomes.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Gestational age at delivery between 34+0 and 36+6 weeks.
  2. Maternal receipt of epidural analgesia during the index labor.
  3. Sufficient maternal medication and neonatal outcome documentation.

Exclusion criteria

Exclusion Criteria:

  1. Congenital malformations expected to affect respiratory drive, airway patency, or cardiopulmonary adaptation
  2. Missing or unreliable maternal medication records that prevent exposure classification.
  3. Insufficient documentation to determine the primary outcome.
  4. Additional systemic opioid exposure that prevents meaningful classification according to the prespecified protocol.
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
320 participants (estimated)
Patient registry
No

Groups and cohorts

  • Late-Preterm Newborns Exposed to Maternal Intrapartum Pethidine

    160 late-preterm newborns (34+0 to 36+6 weeks of gestation) born to mothers who received intrapartum pethidine (meperidine), administered as part of routine clinical care at a planned dose of 50 mg administered via intramuscular (IM) or intravenous (IV) injection alongside combined spinal-epidural analgesia using bupivacaine and fentanyl, administered via the intrathecal and epidural route according to the institutional anesthesia protocol and individual clinical requirements.

    Drug: pethidine hydrochloride

  • Late-Preterm Newborns Without Maternal Intrapartum Pethidine Exposure

    160 late-preterm newborns (34+0 to 36+6 weeks of gestation) born to mothers who received combined spinal-epidural (CSE) analgesia using bupivacaine and fentanyl, administered via the intrathecal and epidural route according to the institutional anesthesia protocol and individual clinical requirements without intrapartum pethidine exposure.

Interventions

  • Drugpethidine hydrochloride

    Maternal intrapartum exposure to pethidine (meperidine), administered as part of routine clinical care at a planned dose of 50 mg administered via intramuscular (IM) or intravenous (IV) injection to facilitate cervical effacement and dilatation alongside combined spinal-epidural analgesia using bupivacaine and fentanyl, administered via the intrathecal and epidural route according to the institutional anesthesia protocol and individual clinical requirements. Pethidine administration is determined independently by the treating clinical team based on the mother's clinical condition and cervical assessment, and is not assigned or controlled by study investigators. The precise dose, route, cumulative amount, and timing/interval from administration to delivery will be prospectively documented to evaluate their association with neonatal respiratory outcomes in late-preterm newborns (34+0 to 36+6 weeks of gestation).

    Also known as: Meperidine

06

What researchers measure

Primary outcomes

  1. Incidence of Clinically Significant Neonatal Respiratory Depression Within 24 Hours After Birth

    Clinically significant neonatal respiratory depression is defined as apnea, gasping, or inadequate respiratory effort requiring active resuscitation or respiratory intervention beyond routine initial newborn care. This includes the need for positive-pressure ventilation (PPV), or recurrent apnea or persistent inadequate respiratory effort requiring escalation of respiratory support. The incidence will be calculated as the proportion of newborns experiencing at least one qualifying episode within the first 24 hours after birth. The association between maternal intrapartum pethidine exposure and this outcome will be assessed. Results will be reported as the number of affected newborns divided by the total number of newborns in each study group (n/N), and expressed as a percentage. Unit of Measure: Number of participants (newborns) experiencing clinically significant neonatal respiratory depression.

    Time frame: From birth through the first 24 hours of life

Secondary outcomes

  1. Neonatal Resuscitation at Birth

    The need for active neonatal resuscitation beyond routine initial newborn care will be recorded, including positive-pressure ventilation (PPV) and other advanced resuscitation interventions, if required. The proportion of newborns requiring resuscitation will be calculated for each study group. Unit of Measurement: Number of participants (newborns) requiring active resuscitation.

    Time frame: At birth, during initial neonatal resuscitation

  2. Need for Neonatal Respiratory Support

    The requirement for respiratory support beyond routine initial newborn care will be recorded, including supplemental oxygen, continuous positive airway pressure (CPAP), non-invasive ventilation, and mechanical ventilation. The highest level of respiratory support required by each newborn during the assessment period will be documented. Unit of Measurement: Number of participants (newborns) requiring respiratory support.

    Time frame: From birth through the first 24 hours of life

  3. Association Between the Pethidine-to-Delivery Interval and Neonatal Respiratory Depression

    The association between the time interval from the maternal intrapartum pethidine administration to delivery and the occurrence of clinically significant neonatal respiratory depression will be evaluated. The interval will be calculated from the time of the last pethidine dose to the time of birth. The incidence of neonatal respiratory depression within the first 24 hours after birth will be analyzed in relation to this interval. Unit of Measurement: Time interval (minutes or hours) between the maternal pethidine dose and delivery; number of newborns experiencing clinically significant respiratory depression.

    Time frame: From the maternal pethidine administration until delivery, with neonatal respiratory depression assessed from birth through the first 24 hours of life.

  4. Apgar Scores

    Neonatal Apgar scores will be recorded at 1 and 5 minutes after birth. Each assessment will include heart rate, respiratory effort, muscle tone, reflex irritability, and skin color, with a total score ranging from 0 to 10 at each assessment. Unit of Measurement: Apgar score (0-10).

    Time frame: At 1 and 5 minutes after birth

  5. Neonatal Blood pH

    Neonatal blood pH will be assessed using umbilical cord blood gas analysis at birth and neonatal blood gas analysis approximately 2 hours after birth to evaluate neonatal acid-base status. Results from both sampling time points will be recorded separately. Unit of Measurement: pH (unitless).

    Time frame: At birth (umbilical cord blood) and approximately 2 hours after birth (neonatal blood gas)

  6. Neonatal Partial Pressure of Carbon Dioxide (PaCO₂)

    Neonatal partial pressure of carbon dioxide (PaCO₂) will be measured using umbilical cord blood gas analysis at birth and neonatal blood gas analysis approximately 2 hours after birth to evaluate neonatal ventilation status. Results from both sampling time points will be recorded separately. Unit of Measurement: mmHg.

    Time frame: At birth (umbilical cord blood) and approximately 2 hours after birth (neonatal blood gas)

  7. Neonatal Partial Pressure of Oxygen (PaO₂)

    Neonatal partial pressure of oxygen (PaO₂) will be measured using umbilical cord blood gas analysis at birth and neonatal blood gas analysis approximately 2 hours after birth to assess neonatal oxygenation status. Results from both sampling time points will be recorded separately. Unit of Measurement: mmHg.

    Time frame: At birth (umbilical cord blood) and approximately 2 hours after birth (neonatal blood gas)

  8. Neonatal Bicarbonate Concentration (HCO₃-)

    Neonatal bicarbonate concentration (HCO₃-) will be measured using umbilical cord blood gas analysis at birth and neonatal blood gas analysis approximately 2 hours after birth to evaluate neonatal metabolic acid-base status. Results from both sampling time points will be recorded separately. Unit of Measurement: mmol/L.

    Time frame: At birth (umbilical cord blood) and approximately 2 hours after birth (neonatal blood gas)

  9. Neonatal Blood Lactate Concentration

    Neonatal blood lactate concentration will be measured using umbilical cord blood gas analysis at birth and neonatal blood gas analysis approximately 2 hours after birth to assess metabolic status and identify evidence of tissue hypoperfusion. Results from both sampling time points will be recorded separately. Unit of Measurement: mmol/L.

    Time frame: At birth (umbilical cord blood) and approximately 2 hours after birth (neonatal blood gas)

  10. Neonatal Lung Ultrasound Score

    Neonatal lung aeration will be assessed using a standardized six-region lung ultrasound examination. Each region will be scored from 0 to 3, producing a total lung ultrasound score ranging from 0 to 18, with higher scores indicating greater lung aeration impairment. Lung ultrasound findings will be evaluated to identify physiological transitional lung patterns and abnormalities suggestive of pulmonary pathology, including retained lung fluid and consolidation, helping to identify alternative or coexisting pulmonary causes of neonatal respiratory distress. Unit of Measurement: Lung ultrasound score (0-18).

    Time frame: Within the first 24 hours after birth

  11. Neonatal Feeding Difficulties

    The occurrence of neonatal feeding difficulties will be assessed, including poor sucking, impaired coordination of sucking and swallowing, and feeding intolerance. The need for feeding assistance will also be documented. The proportion of newborns experiencing feeding difficulties will be calculated. Unit of Measurement: Number of participants (newborns) experiencing feeding difficulties.

    Time frame: From birth through the first 24 hours of life

  12. Neonatal Intensive Care Unit (NICU) Admission

    The number and proportion of newborns requiring admission to the neonatal intensive care unit (NICU) will be recorded. The primary clinical indication for NICU admission, including respiratory or other neonatal complications, will be documented at the time of admission. Unit of Measurement: Number of participants (newborns) admitted to the NICU.

    Time frame: From birth through the first 24 hours of life

  13. Maternal Pain Intensity During Labour

    Maternal pain intensity and the mother's overall experience of labour pain will be assessed in both study groups using the Numeric Rating Scale (NRS), ranging from 0 (no pain) to 10 (worst imaginable pain). Each mother will be asked to provide an overall rating of the pain experienced during labour. The scores will be compared between the pethidine-exposed and unexposed groups. Unit of Measurement: Numeric Rating Scale score (0-10).

    Time frame: Within the first 24 hours after delivery, covering the mother's overall experience of labour pain from the onset of labour until delivery.

  14. Duration of Active Labour and Labour Progression

    The duration of active labour following intrapartum pethidine administration will be assessed from the time of pethidine administration until delivery. Labour progression will be evaluated by documenting cervical dilatation (cm) and cervical effacement (%) at subsequent obstetric examinations following pethidine administration until delivery. The association between maternal pethidine exposure and labour progression will be assessed. Unit of Measurement: Time from pethidine administration to delivery (hours); cervical dilatation (cm); cervical effacement (%).

    Time frame: From pethidine administration until delivery

  15. Maternal Adverse Effects Associated With Intrapartum Pethidine Exposure

    The occurrence of maternal adverse effects associated with intrapartum pethidine administration will be monitored and documented. Potential adverse effects include nausea, vomiting, dizziness, sedation, pruritus, hypotension, and respiratory depression. The type, occurrence, and any required clinical management of adverse effects will be recorded. The incidence of maternal adverse effects will be compared between the pethidine-exposed and unexposed study groups. Unit of Measurement: Number of participants experiencing at least one maternal adverse effect.

    Time frame: From pethidine administration until delivery

07

Study locations

No study locations are listed for this record.

08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Dec 2026; primary completion for Apr 2027, 4 months later.

Of 373 non-industry observational studies under Premature Birth, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 63. This study's planned 4 months is below that.

Counting every sponsor, half of 388 studies reached it within 35 months; a quarter within 19 and three quarters within 61.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 8, 2026
First posted
Nov 17, 2026
StartEst.
Dec 1, 2026
Primary completionEst.
Apr 1, 2027
CompletionEst.
May 1, 2027
Last update
Nov 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 17, 2026
Show all 1 update
  1. Nov 17, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07941986
Lead sponsor
Egyptian Chinese University
Responsible party
Sponsor
First posted
Nov 17, 2026
Start date
Dec 1, 2026 (estimated)
Primary completion
Apr 1, 2027 (estimated)
Completion
May 1, 2027 (estimated)
Last update
Nov 17, 2026

Study contacts

Mustafa Alfiki, MSc, PharmD
Contact
mustafa.alfiki@gmail.com
0096555021180
Dr. Sarah Nafea, PhD, MSc
Contact
Drsarahsabry511@gmail.com
00201068289698
Dr. Noha Nassar, PhD, MSc
study chair · Faculty of Pharmacy, Cairo University, Egypt
Dr. Sarah Nafea, PhD, MSc
study director · Faculty of Pharmacy and Drug Technology, Egyptian Chinese University, Egypt
Dr. Mahmoud Negm, PhD, MBBS
study director · Faculty of Medicine, Zagazig University
Dr. Nora Abdel Rasheed, PhD, MSc
study director · Faculty of Pharmacy, Cairo University, Egypt
Mustafa Alfiki, MSc, PharmD
principal investigator · Faculty of Pharmacy, Cairo University, Egypt; Royale Hayat Hospital, Kuwait

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion